Results 41 to 50 of about 6,010 (179)

Epoprostenol‐associated ascites in pulmonary arterial hypertension

Pulmonary Circulation, 2022
The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre‐existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis.
Noah C. Schoenberg, Nicole F. Ruopp, Raj D. Parikh, Harrison W. Farber   +3 more
doaj   +1 more source

Should We Change the Target of Therapy in Pulmonary Hypertension?

Life, 2023
Despite the evolution of drug therapy in pulmonary arterial hypertension and the more aggressive treatment approach according to the guidelines, patients continue to have unacceptable mortality rates.
Panagiotis Karyofyllis, Eftychia Demerouti, Pavlos Habibis, Styliani Apostolopoulou, Eleftheria-Garyfallia Tsetika, Dimitrios Tsiapras   +5 more
doaj   +1 more source

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

Drug Delivery, 2018
Pulmonary arterial hypertension (PAH) can be relieved by pharmacological interventions, especially the targeted drug, which is classified into endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostaglandin I2, soluble guanylate cyclase ...
Sumei Wang, Miao Yu, Xiangchun Zheng, Shangjuan Dong   +3 more
doaj   +1 more source

Transfusion of blood products to neonatal and pediatric extracorporeal membrane oxygenation patients: A prospective, observational study

Transfusion, EarlyView.
Abstract Study Question To describe the blood product utilization during neonatal and pediatric extracorporeal membrane oxygenation (ECMO) and to determine whether its usage correlates with clinical outcomes of bleeding, thrombosis or mortality. Design Prospective observational study of neonatal and pediatric ECMO patients from September 2016, until ...
Rebecca Barton, Suelyn Van Den Helm, Hui Ping Yaw, Chantal Attard, Graeme MacLaren, Vera Ignjatovic, Natasha Letunica, Vasiliki Karlaftis, Tengyi Cai, Amy Johansen, Derek Best, Roberto Chiletti, Yves d'Udekem, Jo McKittrick, Warwick Butt, Paul Monagle   +15 more
wiley   +1 more source

Epoprostenol (prostacyclin) and severe arterial disease:a double-blind trial

, 1983
A 96 h infusion of epoprostenol (prostacyclin) or placebo was given as a treatment for rest pain to 28 patients with severe peripheral arterial disease.
Leiberman, P., McArdle, B., Lowe, G. D. O., Mckay, A., Pollock, J. G., Forbes, C. D., Prentice, C. R. M., Belch, J. J. F.; id_orcid   +7 more
core   +1 more source

Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation

Platelets, 2022
Prostacyclin (PGI2) analogues (epoprostenol, treprostonil, iloprost) are the cornerstone of pulmonary arterial hypertension (PAH) treatment. PGI2 analogues inhibit platelet reactivity, but their impact on coagulation and fibrinolysis parameters has not ...
Aleksander Siniarski, Aleksandra Gąsecka, Miłosz Starczyński, Marta Banaszkiewicz, Szymon Darocha, Adam Torbicki, Marcin Kurzyna, Krzysztof J. Filipiak, Jadwiga Nessler, Grzegorz Gajos   +9 more
doaj   +1 more source

Impact of Inhaled Epoprostenol in Patients on COVID-19 Acute Respiratory Distress Syndrome (ARDS)

, 2023
BACKGROUND: Coronavirus disease 2019 (COVID-19), a novel respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can progress to critical illness and the development of acute respiratory distress syndrome (ARDS ...
McCoy, Joseph, Dey, Surajit, Nguyen, Stacey, Stephen Chromi, Joseph McCoy, Stacey Nguyen, Jeffrey Murawsky, Decerbo, Mark, Murawsky, Jeffrey, Mark Decerbo, Surajit Dey, Chromi, Stephen   +11 more
core   +1 more source

Epoprostenol Exposure During Pregnancy

Critical Care Explorations, 2023
Institutional policies restricting pregnant providers from caring for patients receiving inhaled epoprostenol exist across the nation based on little to no data to substantiate this practice.
Emily E. Naoum, MD, Carolyn LaVita, MHA, RRT, Natasha Lopez, PharmD, BCCCP, Alexa Nardone, PharmD, BCCCP, Marti D. Soffer, MD, MPH, Kenneth T. Shelton, MD   +5 more
doaj   +1 more source

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula, Ednan K. Bajwa, Alexandra G. Cornell, Maria Jose Loureiro, Samuel S. Kim, Julia Richmond DiBello, Eric Sterner, Richard Chen, Islam R. Younis   +8 more
wiley   +1 more source

Table1_Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease.docx

, 2023
Pulmonary hypertension (PH) with developmental lung disease is a life-threatening disease and accounts for 10%–12% of pediatric PH patients. Administration of specific pulmonary vasodilators to pediatric PH patients has brought about improvement of their
Miharu Ito (9178220), Hidenori Yamamoto (14712100), Yoshiaki Sato (2170141), Yoshie Fukasawa (14712097), Kiyotaka Go (14712103), Yoshihito Morimoto (14712106), Akiko Saito (574853), Kazushi Yasuda (9406412), Masahiro Hayakawa (4849867), Taichi Kato (695773)   +9 more
core   +1 more source